Diketone compound with activity of resisting non-small cell lung cancer

By developing diketone compounds with anti-non-small cell lung cancer activity, the problem of lack of LTK selective inhibitors in the prior art was solved, and effective inhibition of CLIP1-LTK fusion-positive non-small cell lung cancer cells and LTK enzymes was achieved. , demonstrated significant therapeutic effects.

CN119015283APending Publication Date: 2024-11-26WEIFANG UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411255264.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art lacks selective small molecule inhibitors against LTK, and the protein structure of LTK has not been resolved yet, making it difficult to develop effective targeted therapeutic drugs to treat CLIP1-LTK fusion-positive non-small cell lung cancer.

Method used

Provided is a diketone compound with anti-non-small cell lung cancer activity, with a structure of 4-phenyl-7,8,9,10-tetrahydro-2H-isochromeno[3,4-d]pyridazine-1,6- dione, used to prepare anti-non-small cell lung cancer drugs and LTK inhibitors, demonstrated good inhibitory activity on Ba/F3-CLIP1-LTK cells and LTK enzymes.

Benefits of technology

The compound showed significant inhibitory activity against Ba/F3-CLIP1-LTK cells and LTK enzymes at different concentrations, with semi-inhibitory concentrations of 0.49 μM/L and 4.23 μM/L, respectively, showing potential therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015283A_ABST
    Figure CN119015283A_ABST
Patent Text Reader

Abstract

The invention discloses application of a diketone compound with anti-non-small cell lung cancer activity in preparation of anti-non-small cell lung cancer drugs. In inhibitory activity experiments on Ba / F3-CLIP1-LTK cells and LTK enzyme, the diketone compounds with different concentrations provided by the invention show good inhibitory activity, the half inhibitory concentrations IC50 of the diketone compounds are 0.49 mu M / L and 4.23 mu M / L respectively, and the diketone compounds have good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the pharmaceutical field, and in particular to diketone compounds with anti-non-small cell lung cancer activity. Background Art

[0002] Lung cancer is mainly divided into two categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which non-small cell lung cancer accounts for as much as 85%. Stratified targeted therapy for carcinogenic factors has significantly improved the treatment effect of lung cancer patients, especially the survival rate of lung cancer patients carrying specific carcinogenic factors has been greatly improved. Gene fusion-activated protein kinases are an important class of oncogenes closely related to hematopoietic malignancies and solid tumors. They are usually generated by chromosomal translocations or other rearrangement events, and the protein products they encode are often ideal targets for the development of anticancer drugs.

[0003] Relying on the clinical sample resources of the Asian Lung Cancer Genome Screening Platform (LC-SCRUM-Asia), the researchers conducted whole transcriptome sequencing analysis on non-small cell lung cancer samples with unknown driver genes. Through experimental methods such as RT-PCR technology, Sanger sequencing, and fluorescence in situ hybridization (FISH), specific transcripts encoding CLIP1-LTK protein were finally found in the tumor samples of these patients. Further transformation experiments showed that the CLIP1-LTK fusion protein, depending on its own kinase activity, exhibited the ability to cause oncogenic transformation in NIH3T3 fibroblasts and Ba / F3 pro-B lymphocytes. This discovery confirms that the CLIP1-LTK fusion protein is a new oncogenic driver, providing a key new target for the development of targeted therapeutic drugs for non-small cell lung cancer.

[0004] As a member of the microtubule end tracer protein family, CLIP1 binds to microtubules through its N-terminal CAP-Gly domain and participates in a variety of microtubule-related intracellular activities, such as the connection between centromeres and microtubules during mitosis, directional cell migration, etc. In addition, CLIP1 can also interact with other microtubule-binding proteins, such as EB1 protein and CLASP family proteins that are also located at the plus end of microtubules, so as to more accurately locate at the plus end of microtubules.

[0005] LTK is a member of the receptor tyrosine kinase family, and its protein sequence includes an extracellular region, a transmembrane region, and an intracellular tyrosine kinase region. The intracellular region is composed of a juxtamembrane region, a protein kinase domain, and a carboxyl terminus. The protein kinase domain contains a smaller N-terminal lobe and a larger C-terminal lobe, with the ATP binding site located between the two. The protein sequences of LTK and ALK are highly homologous, especially the identity of the kinase domain sequence can reach 79%, but the extracellular domain structure of LTK is relatively small, containing only two MAM domains. At present, there are few studies on the biological function of wild-type LTK, and the only studies suggest that it may play a role in animal autoimmunity and neural development. The protein fusion of CLIP1 and LTK is the key to cell carcinogenic transformation. Importantly, in tumor samples positive for the CLIP1-LTK fusion gene, other known oncogenic driver genes were negative, indicating that the CLIP1-LTK fusion gene is mutually exclusive with other known driver genes, and therefore is expected to become a potential target for the treatment of CLIP1-LTK fusion-positive cancer patients.

[0006] At present, there are no reports of selective small molecule inhibitors for LTK, and the protein structure of LTK has not yet been resolved. Those skilled in the art continue to work on developing LTK inhibitors with novel structures and better effects, in order to expand the range of clinical drug options.

[0007] It is a compound in the commercial compound library, and its IUPAC name is 4-phenyl-7,8,9,10-tetrahydro-2 H -isochromeno[3,4-d]pyridazine-1,6-dione, no studies have shown that it has any particular activity. Summary of the invention

[0008] The object of the present invention is to overcome at least one of the deficiencies of the prior art and to provide diketone compounds having anti-non-small cell lung cancer activity.

[0009] The technical solution adopted by the present invention is: In a first aspect, the present invention provides a use of a diketone compound or an acceptable derivative thereof in the preparation of an anti-non-small cell lung cancer drug, wherein the diketone compound has a structure as shown in the following formula: ; In the formula, the R group is selected from H and C1-C4 alkane groups.

[0010] In some examples, the R group is H.

[0011] In some examples, the derivative of the diketone compound is a pharmaceutically acceptable salt thereof.

[0012] In some examples, the non-small cell lung cancer disease includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

[0013] In some examples, the non-small cell lung cancer is CLIP1-LTK fusion gene positive non-small cell lung cancer.

[0014] In some examples, the drug further comprises a pharmaceutically acceptable excipient, wherein the excipient comprises at least one of a solvent, a filler, a lubricant, a disintegrant, a buffer, a solubilizing agent, an antioxidant, an antibacterial agent, an emulsifier, a binder or a suspending agent.

[0015] In some examples, the drug is in the form of an intravenous injection, a suppository, a gel, a foam, an enteric solvent, a decoction, a mixture, a syrup, a granule, a pill, a capsule, a gel or a nanoformulation.

[0016] In a second aspect, the present invention provides a diketone compound or an acceptable derivative thereof for use in preparing an experimental LTK inhibitor, wherein the diketone compound has a structure shown in the following formula: ; In the formula, the R group is selected from H, C1-C4 alkane group; The use does not include treatment of disease.

[0017] In some examples, the R group is H.

[0018] In some examples, the derivative of the diketone compound is a pharmaceutically acceptable salt thereof.

[0019] The beneficial effects of the present invention are: When the diketone compounds of different concentrations provided in the present invention were subjected to the inhibitory activity experiments on Ba / F3-CLIP1-LTK cells and LTK enzyme, the compounds all showed good inhibitory activity, and their half inhibitory concentration IC 50 0.49 μM / L and 4.23 μM / L respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The figure shows the inhibition curve of different concentrations of the diketone compounds provided in the present invention on Ba / F3-CLIP1-LTK.

[0021] Figure 2 The figure shows the inhibition curve of LTK by the diketone compounds of different concentrations provided in the present invention. DETAILED DESCRIPTION

[0022] The following disclosure provides many different embodiments or examples for implementing different solutions of the present invention.

[0023] Anti-cell proliferation activity assay Experimental principle: The anti-cell proliferation effect of the compound is determined using the MTT (thiazolyl blue) experiment. MTT can be reduced to water-insoluble blue-purple crystalline formazan by succinate dehydrogenase in the cell mitochondria and deposited in living cells, while dead cells do not have this function. Dimethyl sulfoxide can dissolve the formazan in the cells, and its light absorption value can be measured at a wavelength of 570nm by an enzyme-linked immunosorbent assay, which can indirectly reflect the number of living cells.

[0024] Experimental method: MTT colorimetry was used to evaluate cell proliferation activity in the constructed Ba / F3-CLIP1-LTK cell line.

[0025] During the experiment, Ba / F3-CLIP1-LTK cell suspension was first prepared using RPMI-1640 medium without IL-3, and 90 μL of the cell suspension was inoculated in each well of a 96-well plate. Subsequently, the 96-well plate was placed in a cell culture incubator for 2 hours, and then 8 groups of diketone compounds or dimethyl sulfoxide with concentration gradients (concentrations were 0.87 nmol / l, 4.35 nmol / l, 21.75 nmol / l, 32 nmol / l, 543.64 nmol / l, 2718.22 nmol / l, 13591.11 nmol / l and 67955.56 nmol / l) were added to each well.

[0026] After 72 hours of incubation, 10 μL of MTT solution was added to each well and incubated for another 4 hours. After that, 100 μL of SDS-HCl-PBS triple buffer solution was added to dissolve the formed formazan crystals. Finally, the absorbance value of each well at 570 nm was monitored using a microplate reader, and the data were fitted into a concentration-response curve with a variable slope, from which the IC 50 value.

[0027] Experimental results: The anti-proliferation experiment of Ba / F3-CLIP1-LTK cells was carried out using diketone compounds at different concentrations. It was found that the compound had a good inhibitory activity on Ba / F3-CLIP1-LTK cells, and its half inhibitory concentration IC 50 0.49μM / L( Figure 1 ).

[0028] LTK enzyme inhibition activity assay Experimental principle: The LTK inhibitory activity is measured using the LanthaScreenTM kinase assay based on TR-FRET technology to determine the kinase inhibitory activity of candidate compounds.

[0029] Experimental methods: All experiments were performed in 384-well plates. Before the experiment, 8 diketone compound solutions with different concentrations (0.87 nmol / l, 4.35 nmol / l, 21.75 nmol / l, 32 nmol / l, 543.64 nmol / l, 2718.22 nmol / l, 13591.11 nmol / l and 67955.56 nmol / l) were prepared. Then, 4 sets of recombinant human LTK proteins and 2 sets of substrate / ATP mixtures were prepared in a buffer solution containing 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA and 2 mM DTT4.

[0030] The final kinase reaction system contains 10 μL of mixture, including 5 μL of 1× substrate / ATP mixture (0.2 μM substrate and 5 μM ATP), 2.5 μL of LTK protein (5 ng / ml), and 2.5 μL of 1× test compound at the desired concentration. The assay plate is shaken on a shaker for 30 seconds to ensure that the reaction is well mixed. Then, the kinase reaction is allowed to proceed for 1 hour at room temperature (20–25 °C).

[0031] Afterwards, 10 μL of pre-prepared stop solution (containing 20 mM EDTA and 4 nM Tb-labeled antibody) was added to terminate the kinase reaction and trigger antibody binding, and the assay plate was incubated for 1 hour at room temperature. Subsequently, the emission signals of fluorescein and terbium (excitation wavelength of 340 nm; emission wavelengths of 520 nm and 495 nm, respectively) were measured using a fluorescence plate reader (BioTek SynergyTM 4) with a delay time of 100 μs and an integration time of 200 μs.

[0032] Finally, the inhibitory activity was calculated based on the TR-FRET emission ratio (i.e., the ratio of the emission intensity of fluorescein to the emission intensity of terbium) and plotted against the concentration of the inhibitor. The data were fitted to a concentration-response curve with a variable slope, from which the IC50 value was calculated.

[0033] Experimental results: The enzyme inhibition activity of LTK was tested using diketone compounds at different concentrations. It was found that the compound had good inhibitory activity, and its half inhibitory concentration IC 50 4.23 μM / L( Figure 2 ).

[0034] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.

Claims

1. Use of a diketone compound or an acceptable derivative thereof in the preparation of an anti-non-small cell lung cancer drug, characterized in that: The diketone compound has a structure as shown in the following formula: ; In the formula, the R group is selected from H and C1-C4 alkane groups.

2. The use according to claim 1, characterized in that: The R group is H.

3. The use according to claim 1, characterized in that: The derivatives of the diketone compounds are pharmaceutically acceptable salts thereof.

4. The use according to claim 1, characterized in that: The non-small cell lung cancer disease includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma.

5. The use according to claim 1 or 4, characterized in that: The non-small cell lung cancer is CLIP1-LTK fusion gene positive non-small cell lung cancer.

6. The use according to claim 1, characterized in that: The drug also includes pharmaceutically acceptable excipients, which include at least one of solvents, fillers, lubricants, disintegrants, buffers, solubilizers, antioxidants, antibacterial agents, emulsifiers, binders or suspending agents.

7. The use according to claim 1, characterized in that: The dosage form of the drug is intravenous injection, suppository, gel, foam, enteric solvent, decoction, mixture, syrup, granule, pill, capsule, gel or nano preparation.

8. Use of a diketone compound or an acceptable derivative thereof in the preparation of an experimental LTK inhibitor, characterized in that: The diketone compound has a structure shown in the following formula: ; In the formula, the R group is selected from H, C1-C4 alkane group; The use does not include the treatment of disease.

9. The use according to claim 8, characterized in that: The R group is H.

10. The use according to claim 9, characterized in that: The derivatives of the diketone compounds are pharmaceutically acceptable salts thereof.